---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000019"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:18:04.745004+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ivonescimab Phase II shows 64.8% 24-month OS in 1L squamous NSCLC; cash ≥$186M

## Summary
- Phase II AK112-201: 24-month OS rate 64.8% in 63 1L squamous NSCLC patients; median OS not reached after 21.0 months follow-up.
- In 19 2L+ EGFRm NSCLC patients (post-TKI), median OS 22.5 months; 12-month OS rate 74%.
- Near-term catalysts: Chinese NDA decision for AK112-301 (Q2 2024) and interim analysis of AK112-303 vs. pembrolizumab (Q2 2024).
- Preliminary cash, cash equivalents, and short-term investments at least $186M as of Dec 31, 2023 (unaudited).
- Two global Phase III trials ongoing: HARMONi (EGFRm NSCLC) and HARMONi-3 (1L squamous NSCLC vs. pembrolizumab).

## SEC filing metadata
- accession: 0001599298-24-000019
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000019/0001599298-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000019/smmt-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000019
- JSON: https://secwatch.observer/filing/0001599298-24-000019.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.